Show simple item record

dc.contributor.authorMacleod, Malcolm R.
dc.contributor.authorFisher, Marc
dc.contributor.authorO'Collins, Victoria
dc.contributor.authorSena, Emily S.
dc.contributor.authorDirnagl, Ulrich
dc.contributor.authorBath, Philip M.W.
dc.contributor.authorBuchan, Alistair
dc.contributor.authorvan der Worp, H. Bart
dc.contributor.authorTraystman, Richard
dc.contributor.authorMinematsu, Kazuo
dc.contributor.authorDonnan, Geoffrey A.
dc.contributor.authorHowells, David W.
dc.date2022-08-11T08:09:28.000
dc.date.accessioned2022-08-23T16:31:38Z
dc.date.available2022-08-23T16:31:38Z
dc.date.issued2008-08-16
dc.date.submitted2010-03-24
dc.identifier.citationStroke. 2009 Mar;40(3):e50-2. Epub 2008 Aug 14. <a href="http://dx.doi.org/10.1161/STROKEAHA.108.525386">Link to article on publisher's site</a>
dc.identifier.issn0039-2499 (Linking)
dc.identifier.doi10.1161/STROKEAHA.108.525386
dc.identifier.pmid18703798
dc.identifier.urihttp://hdl.handle.net/20.500.14038/37693
dc.description.abstractBACKGROUND AND PURPOSE: As a research community, we have failed to demonstrate that drugs which show substantial efficacy in animal models of cerebral ischemia can also improve outcome in human stroke. Summary of Review- Accumulating evidence suggests this may be due, at least in part, to problems in the design, conduct and reporting of animal experiments which create a systematic bias resulting in the overstatement of neuroprotective efficacy. CONCLUSIONS: Here, we set out a series of measures to reduce bias in the design, conduct and reporting of animal experiments modeling human stroke.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=18703798&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1161/STROKEAHA.108.525386
dc.subjectAnimals
dc.subject*Bias (Epidemiology)
dc.subjectConflict of Interest
dc.subjectDisease Models, Animal
dc.subjectDrug Industry
dc.subjectHumans
dc.subjectRandom Allocation
dc.subjectResearch Design
dc.subjectResearch Support as Topic
dc.subjectSample Size
dc.subjectStroke
dc.subjectTreatment Outcome
dc.subjectNeurology
dc.subjectNeuroscience and Neurobiology
dc.titleGood laboratory practice: preventing introduction of bias at the bench
dc.typeJournal Article
dc.source.journaltitleStroke; a journal of cerebral circulation
dc.source.volume40
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/neuro_pp/368
dc.identifier.contextkey1242240
html.description.abstract<p>BACKGROUND AND PURPOSE: As a research community, we have failed to demonstrate that drugs which show substantial efficacy in animal models of cerebral ischemia can also improve outcome in human stroke. Summary of Review- Accumulating evidence suggests this may be due, at least in part, to problems in the design, conduct and reporting of animal experiments which create a systematic bias resulting in the overstatement of neuroprotective efficacy.</p> <p>CONCLUSIONS: Here, we set out a series of measures to reduce bias in the design, conduct and reporting of animal experiments modeling human stroke.</p>
dc.identifier.submissionpathneuro_pp/368
dc.contributor.departmentDepartment of Neurology
dc.source.pagese50-2


This item appears in the following Collection(s)

Show simple item record